Next Article in Journal
Leptin-Induced JAK/STAT Signaling and Cancer Growth
Next Article in Special Issue
From Immunologically Archaic to Neoteric Glycovaccines
Previous Article in Journal
Factors that Influence the Immunological Adjuvant Effect of Lactobacillus fermentum PC1 on Specific Immune Responses in Mice to Orally Administered Antigens
Previous Article in Special Issue
Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses
Article Menu

Export Article

Open AccessReview
Vaccines 2016, 4(3), 25;

Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines

Department of Medicinal and Biological Chemistry, University of Toledo, Toledo, OH 43606, USA
Author to whom correspondence should be addressed.
Academic Editor: Diane M. Harper
Received: 19 April 2016 / Revised: 13 July 2016 / Accepted: 21 July 2016 / Published: 26 July 2016
(This article belongs to the Special Issue Glycopeptide-based and Related Vaccines)
Full-Text   |   PDF [819 KB, uploaded 26 July 2016]   |  


Aberrantly glycosylated mucin 1 (MUC1) is a recognized tumor-specific antigen on epithelial cell tumors. A wide variety of MUC1 glycopeptide anti-cancer vaccines have been formulated by many research groups. Some researchers have used MUC1 alone as an immunogen whereas other groups used different antigenic carrier proteins such as bovine serum albumin or keyhole limpet hemocyanin for conjugation with MUC1 glycopeptide. A variety of adjuvants have been used with MUC1 glycopeptides to improve their immunogenicity. Fully synthetic multicomponent vaccines have been synthesized by incorporating different T helper cell epitopes and Toll-like receptor agonists. Some vaccine formulations utilized liposomes or nanoparticles as vaccine delivery systems. In this review, we discuss the immunological evaluation of different conjugate or synthetic MUC1 glycopeptide vaccines in different tumor or mouse models that have been published since 2012. View Full-Text
Keywords: MUC1; adjuvant; BSA; KLH; TLR; liposome; vaccine MUC1; adjuvant; BSA; KLH; TLR; liposome; vaccine

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hossain, M.K.; Wall, K.A. Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines. Vaccines 2016, 4, 25.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top